No Data
No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Is the breakthrough path all in AI? Chain pharmacies are facing a wave of closures and an era of low profits.
① In 2024, particularly in the second half of the year, chain pharmacies will face a large-scale wave of closures, and leading chain pharmacies will generally enter a low-profit era. ② AI is also being assigned higher expectations in helping pharmacies reduce costs and increase efficiency. ③ Publicly available large models, due to a lack of support from vertical domain data, are still insufficient to support the actual Business Operation of pharmacies.
Shenzhen Hepalink to Approve Annual Results and Consider Dividend
HEPALINK (09989.HK) held a Board of Directors meeting on March 28 to consider and approve the annual performance.
Gelonghui reported on March 14 that HEPALINK (09989.HK) announced that a Board of Directors meeting is scheduled for March 28, 2025 (Friday), during which the agenda includes considering and approving the audited annual results of the group for the year ending December 31, 2024, and its publication, as well as considering the proposal for the final dividend distribution (if any).
HEPALINK: DATE OF BOARD MEETING
AI and policy are driving forces! Hong Kong pharmaceutical stocks collectively "rebound" with WUXI BIO surging over 14% to lead the Industry.
① What technological breakthroughs have driven the improvement of research and development efficiency in the Biomedical Industry? ② What are the reasons for the leading increase in WuXi's affiliated companies?